Close



May 18, 2023 07:14AM
May 18, 2023 07:00AM
May 11, 2023 07:00AM
Mar 23, 2023 07:00AM
Dec 7, 2022 04:37PM
Dec 7, 2022 07:30AM
Dec 7, 2022 07:30AM AVROBIO Announces New Positive Clinical Data and Outlines Clinical Development Plan Following Regulatory Discussions for its Gaucher Disease Gene Therapy
Nov 17, 2022 07:03AM
Nov 17, 2022 07:00AM
Nov 8, 2022 07:00AM
Oct 27, 2022 07:03AM
Oct 27, 2022 07:00AM
Oct 25, 2022 07:00AM
Oct 18, 2022 07:02AM AVROBIO Inc. (AVRO) Granted ILAP Designation from U.K. MHRA for First-in-Class Gene Therapy for Gaucher Disease
Oct 18, 2022 07:00AM
Sep 20, 2022 07:00AM
Sep 20, 2022 07:00AM
Sep 14, 2022 07:29AM
Sep 14, 2022 07:28AM
Aug 9, 2022 07:00AM
Jul 13, 2022 07:01AM AVROBIO Inc. (AVRO) Receives Orphan Drug Designation from the U.S. Food and Drug Administration for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter Syndrome
Jul 13, 2022 07:00AM
May 17, 2022 07:00AM
May 17, 2022 07:00AM
Feb 9, 2022 05:16PM
Feb 9, 2022 07:18AM
Feb 9, 2022 07:00AM
Jan 5, 2022 05:28PM Avrobio Inc. (AVRO) PT Lowered to $6 at Mizuho Securities
Nov 4, 2021 07:00AM
Nov 3, 2021 07:00AM
Nov 3, 2021 07:00AM
Aug 5, 2021 07:00AM
Aug 2, 2021 07:00AM
May 13, 2021 07:00AM
May 3, 2021 07:08AM AVROBIO Inc. (AVRO) Provides Regulatory Update on Investigational AVR-RD-01 for Fabry Disease
May 3, 2021 07:00AM
Mar 18, 2021 07:00AM
Mar 1, 2021 07:03AM
Mar 1, 2021 07:00AM
Feb 8, 2021 07:00AM
Nov 17, 2020 07:03AM
Nov 17, 2020 07:00AM AVROBIO Announces New Positive Clinical Data and Preclinical Data, as Well as Expanded Leading Lysosomal Disorder Gene Therapy Pipeline
Nov 5, 2020 07:00AM
Oct 29, 2020 07:00AM
Sep 28, 2020 07:04AM
Sep 28, 2020 07:00AM
Jun 2, 2020 06:39AM
May 7, 2020 07:00AM
Mar 16, 2020 07:00AM AVROBIO Reports Fourth Quarter and Fiscal Year 2019 Financial Results and Provides Business Update
Mar 9, 2020 07:09AM

251,639 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All